PRT-7732
- Generic Name
- PRT-7732
A Study of PRT7732, an Oral SMARCA2 Degrader, in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation
Phase 1
Recruiting
- Conditions
- Metastatic Solid TumorAdvanced Solid TumorNon-small Cell Lung CarcinomaSMARCA4 Mutation
- Interventions
- First Posted Date
- 2024-08-19
- Last Posted Date
- 2025-04-15
- Lead Sponsor
- Prelude Therapeutics
- Target Recruit Count
- 104
- Registration Number
- NCT06560645
- Locations
- 🇺🇸
UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States
🇺🇸Brigitte Harris Cancer Pavilion, Detroit, Michigan, United States
🇺🇸Memorial Sloan Kettering Cancer Center - Main Campus, New York, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath